The effects of neutral argon plasma versus electrocoagulation on tissue in advanced-stage ovarian cancer: a case series

Boer, Gatske M. Nieuwenhuyzen-de; Berg, Nick J. van de; Gao, Xu Shan; Ewing‐Graham, Patricia C.; Beekhuizen, Heleen J. van

doi:10.1186/s13048-022-01070-5

Cited by 2 publications

(2 citation statements)

References 15 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a series of 10 samples collected from 8 women with ovarian endometriomas, a mean depth of necrosis of 145 µm was found [ 22 ]. Finally, thermal effects of PJ and electrosurgical devices were compared in a series of 106 tissue samples of 17 ovarian cancer patients undergoing cytoreductive surgery [ 23 ]. Devices were used in vivo on to-be-resected tissues of reproductive organs, and intestines as well as on membranes.…”

Section: Resultsmentioning

confidence: 99%

Plasma Device Functions and Tissue Effects in the Female Pelvis—A Systematic Review

Berg

Boer

Gao

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Medical use of (non-)thermal plasmas is an emerging field in gynaecology. However, data on plasma energy dispersion remain limited. This systematic review presents an overview of plasma devices, fields of effective application, and impact of use factors and device settings on tissues in the female pelvis, including the uterus, ovaries, cervix, vagina, vulva, colon, omentum, mesenterium, and peritoneum. A search of the literature was performed on 4 January 2023 in the Medline Ovid, Embase, Cochrane, Web of Science, and Google Scholar databases. Devices were classified as plasma-assisted electrosurgery (ES) using electrothermal energy, neutral argon plasma (NAP) using kinetic particle energy, or cold atmospheric plasma (CAP) using non-thermal biochemical reactions. In total, 8958 articles were identified, of which 310 were scanned, and 14 were included due to containing quantitative data on depths or volumes of tissues reached. Plasma-assisted ES devices produce a thermal effects depth of <2.4 mm. In turn, NAP effects remained superficial, <1.0 mm. So far, the depth and uniformity of CAP effects are insufficiently understood. These data are crucial to achieve complete treatment, reduce recurrence, and limit damage to healthy tissues (e.g., prevent perforations or preserve parenchyma). Upcoming and potentially high-gain applications are discussed, and deficits in current evidence are identified.

show abstract

Section: Resultsmentioning

confidence: 99%

Plasma Device Functions and Tissue Effects in the Female Pelvis—A Systematic Review

Berg

Boer

Gao

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…A possible explanation could be the differences in tissue damage when working with different equipment during surgery. The PlasmaJet infiltrates the tissue less deeply than electrosurgery [29]. With less tissue damage, the process of tissue repair (inflammation, proliferation by fibrogenesis, and angiogenesis and remodeling) will proceed differently than when there is more tissue damage.…”

Section: Discussionmentioning

confidence: 99%

Cytoreductive Surgery with the PlasmaJet Improved Quality-of-Life for Advanced Stage Ovarian Cancer Patients

Boer

Aamran

Berg

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

Background: Knowledge of quality-of-life after cytoreductive surgery is important to counsel patients with advanced-stage epithelial ovarian cancer prior to surgery. The aim of this study was to determine whether the use of the PlasmaJet Surgical device during cytoreductive surgery has an effect on the quality-of-life of patients with advanced epithelial ovarian cancer. Methods: Data included in this prospective observational study were derived from the PlaComOv study, in which patients with advanced epithelial ovarian cancer were randomly assigned to have cytoreductive surgery with or without adjuvant use of the PlasmaJet. Quality-of-life was measured before surgery and one, six, 12, and 24 months after surgery with three questionnaires: the EORTC QLQ-C30, QLQ-OV28, and EQ-5D-5L. Results: Between 2018 and 2020, 326 patients were enrolled in the trial. The overall response rate was high, with the lowest response rate at 24 months of 77%. At 6 months, quality-of-life was higher in the intervention group (95%CI 0.009; 0.081, p = 0.045). At 12 months, quality-of-life was higher in the intervention group with fewer symptoms of fatigue, appetite loss, and diarrhea (95%CI 0.6; 10,0, p = 0.027); similarly, patients in the intervention group reported a better body image (95%CI −14.2; −3.0, p = 0.003) and a higher score on the visual analog scale (95%CI 1.99; 11.15, p = 0.005). At 24 months postoperatively, no further difference was found between the two groups except for pain (95%CI −12.9; −0.8, p = 0.027) and body image (95%CI −13.808; −0.733, p = 0.029). A higher quality-of-life in the intervention group was partially explained by the mediator ‘surgery outcome’. Conclusions: This study demonstrated knowledge of patients’ quality-of-life until two years after cytoreductive surgery. The use of the PlasmaJet Surgical device during cytoreductive surgery leads to a higher quality-of-life than conventional surgery with electrocoagulation alone. Even after adjustment for the mediator of surgical outcome, a higher quality-of-life was seen in patients who had surgery with the use of the PlasmaJet device.

show abstract

The effects of neutral argon plasma versus electrocoagulation on tissue in advanced-stage ovarian cancer: a case series

Cited by 2 publications

References 15 publications

Plasma Device Functions and Tissue Effects in the Female Pelvis—A Systematic Review

Plasma Device Functions and Tissue Effects in the Female Pelvis—A Systematic Review

Cytoreductive Surgery with the PlasmaJet Improved Quality-of-Life for Advanced Stage Ovarian Cancer Patients

Contact Info

Product

Resources

About